Last reviewed · How we verify
BromAc
At a glance
| Generic name | BromAc |
|---|---|
| Sponsor | Mucpharm Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nebulised BromAc in Healthy Volunteers (PHASE1)
- BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei (PHASE2)
- Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BromAc CI brief — competitive landscape report
- BromAc updates RSS · CI watch RSS
- Mucpharm Pty Ltd portfolio CI